Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future

Bernstein said Novartis’ decision to discontinue VHB937 for amyotrophic lateral sclerosis (ALS) on September 16 improves the commercial landscape for Zydus Lifesciences’ Usnoflast.

Leave a Reply

Your email address will not be published. Required fields are marked *